Trials / Completed
CompletedNCT00927654
Iloprost in High Risk Cardiac Surgical Patients
Effect of Iloprost Inhalation Before and During Extracorporeal Circulation (ECC) on Perioperative Morbidity and Outcome in High Risk Cardiac Surgical Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 253 (actual)
- Sponsor
- Ludwig-Maximilians - University of Munich · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In this study effects of the intra operative, prophylactic inhalation of Iloprost (Ventavis) before and during extracorporal circulation on perioperative morbidity and outcome in high risk cardiac surgical patients is investigated in comparison to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iloprost (Ventavis) | Twice 20 µg at day 0 (total dose 40 µg) intraoperatively |
| DRUG | Isotonic Sodium Chloride solution 0.9 % (placebo) | Twice at day 0 intraoperatively |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2009-06-25
- Last updated
- 2013-01-07
Locations
6 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00927654. Inclusion in this directory is not an endorsement.